NASDAQ:CMPS Compass Pathways (CMPS) Stock Price, News & Analysis $10.51 +0.14 (+1.36%) As of 12:26 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Compass Pathways Stock (NASDAQ:CMPS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Compass Pathways alerts:Sign Up Key Stats Today's Range$10.47▼$11.6550-Day Range$5.22▼$10.9652-Week Range$2.25▼$11.65Volume4.35 million shsAverage Volume3.56 million shsMarket Capitalization$1.42 billionP/E RatioN/ADividend YieldN/APrice Target$20.58Consensus RatingModerate Buy Company Overview Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S. Food and Drug Administration. In addition to its lead depression program, Compass Pathways is exploring broader applications of psychedelic-assisted therapies in areas such as anorexia nervosa and other mood disorders. The company has built a scalable manufacturing process for synthetic psilocybin and established a network of trained therapists and research sites across Europe and North America. Compass also leverages digital tools to capture patient-reported outcomes and physiological data, supporting personalized treatment protocols and enhancing safety monitoring throughout clinical studies. Since its initial public offering in September 2020, Compass Pathways has advanced its pipeline through rigorous clinical partnerships and academic collaborations. The leadership team is led by co-founder and CEO George Goldsmith, who has guided the company through regulatory milestones and strategic alliances. With a board of directors comprising experts in neuroscience, clinical research, and life sciences commercialization, Compass remains committed to transforming the treatment paradigm for mental health by combining innovative science, patient-centered care, and robust regulatory engagement. AI Generated. May Contain Errors. Read More Compass Pathways Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks72nd Percentile Overall ScoreCMPS MarketRank™: Compass Pathways scored higher than 72% of companies evaluated by MarketBeat, and ranked 180th out of 864 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingCompass Pathways has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 2 strong buy ratings, 8 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCompass Pathways has a consensus price target of $20.58, representing about 98.5% upside from its current price of $10.37.Amount of Analyst CoverageCompass Pathways has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Compass Pathways' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Compass Pathways are expected to decrease in the coming year, from ($0.99) to ($1.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Compass Pathways is -3.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Compass Pathways is -3.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Compass Pathways' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.80% of the float of Compass Pathways has been sold short.Short Interest Ratio / Days to CoverCompass Pathways has a short interest ratio ("days to cover") of 1.15, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Compass Pathways has recently decreased by 11.32%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCompass Pathways does not currently pay a dividend.Dividend GrowthCompass Pathways does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.69 News SentimentCompass Pathways has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 25 news articles for Compass Pathways this week, compared to 5 articles on an average week.Search Interest45 people have searched for CMPS on MarketBeat in the last 30 days. This is an increase of 543% compared to the previous 30 days.MarketBeat Follows14 people have added Compass Pathways to their MarketBeat watchlist in the last 30 days. This is an increase of 1,300% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Compass Pathways insiders have not sold or bought any company stock.Percentage Held by Insiders2.82% of the stock of Compass Pathways is held by insiders.Percentage Held by Institutions46.19% of the stock of Compass Pathways is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Compass Pathways' insider trading history. Receive CMPS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Compass Pathways and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CMPS Stock News HeadlinesResearch Analysts Offer Predictions for CMPS FY2028 EarningsMay 18 at 2:31 AM | americanbankingnews.comLifesci Capital Cuts Earnings Estimates for Compass PathwaysMay 18 at 1:10 AM | americanbankingnews.comThis next market event could mean total financial ruin for someA market signal last detected before the Great Depression may be flashing again - and according to Weiss Ratings, the current volatility could be just the beginning. Analysts have identified ten popular stocks that could fall sharply as this shift plays out, erasing years of portfolio gains. For a limited time during the Memorial Day Sales Event, you can access this list and full Weiss Ratings Plus benefits at 79% off.May 18 at 1:00 AM | Weiss Ratings (Ad)Compass Pathways' (CMPS) "Buy" Rating Reiterated at BTIG ResearchMay 16 at 3:38 AM | americanbankingnews.comCompass Pathways (NASDAQ:CMPS) Upgraded by Wall Street Zen to Hold RatingMay 16 at 1:30 AM | americanbankingnews.comRoyal Bank Of Canada Issues Positive Forecast for Compass Pathways (NASDAQ:CMPS) Stock PriceMay 15 at 3:18 AM | americanbankingnews.comThese 3 Psychedelic Stocks Activated After Trump's Executive OrderPsychedelic drugs could get a big boost thanks to a recent executive order, and these firms all have promising candidates in line.April 27, 2026 | marketbeat.comThis 4/20, Wall Street Is Betting on More Than MarijuanaWall Street is currently pivoting toward high-growth biotech plays as federal support accelerates a revolution in alternative medicine.April 20, 2026 | marketbeat.comSee More Headlines CMPS Stock Analysis - Frequently Asked Questions How have CMPS shares performed this year? Compass Pathways' stock was trading at $6.90 at the beginning of 2026. Since then, CMPS stock has increased by 50.3% and is now trading at $10.37. How were Compass Pathways' earnings last quarter? Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) issued its quarterly earnings data on Wednesday, May, 13th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.15. Read the conference call transcript. When did Compass Pathways IPO? Compass Pathways (CMPS) raised $112 million in an IPO on Friday, September 18th 2020. The company issued 7,500,000 shares at a price of $14.00-$16.00 per share. Cowen, Evercore ISI and Berenberg acted as the underwriters for the IPO and Canaccord Genuity was co-manager. Who are Compass Pathways' major shareholders? Top institutional shareholders of Compass Pathways include Orbimed Advisors LLC (0.89%), Affinity Asset Advisors LLC (0.86%), Renaissance Technologies LLC (0.67%) and Sumitomo Mitsui Trust Group Inc. (0.29%). Insiders that own company stock include Life Sciences NV Atai, Ekaterina Malievskaia and George Jay Goldsmith. View institutional ownership trends. How do I buy shares of Compass Pathways? Shares of CMPS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Compass Pathways own? Based on aggregate information from My MarketBeat watchlists, some other companies that Compass Pathways investors own include Symbotic (SYM), Enovix (ENVX), Rambus (RMBS), JPMorgan Nasdaq Equity Premium Income ETF (JEPQ), Ginkgo Bioworks (DNA), Toast (TOST) and Saia (SAIA). Company Calendar Last Earnings5/13/2026Today5/18/2026RBC Capital Markets Global Healthcare Conference 20265/19/2026Next Earnings (Estimated)7/30/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 CMPS's financial health is in the Green zone, according to TradeSmith. CMPS has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Services Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CMPS CIK1816590 Webwww.compasspathways.com Phone716-676-6461FaxN/AEmployees120Year Founded2016Price Target and Rating Average Price Target for Compass Pathways$20.58 High Price Target$70.00 Low Price Target$6.00 Potential Upside/Downside+95.0%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($3.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$287.86 million Net MarginsN/A Pretax MarginN/A Return on Equity-31.07% Return on Assets-11.40% Debt Debt-to-Equity Ratio0.15 Current Ratio3.32 Quick Ratio3.32 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.55) per share Price / Book-19.19Miscellaneous Outstanding Shares134,950,000Free Float131,143,000Market Cap$1.42 billion OptionableOptionable Beta2.39 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:CMPS) was last updated on 5/18/2026 by MarketBeat.com Staff. From Our PartnersBNZI Update: Zacks Buy Rating Sparks Fresh Momentum!Banzai International (NASDAQ: BNZI) delivered full-year 2025 revenue of $12.2 million, a 169% year-over-year i...Huge Alerts | SponsoredMemorial Day Sale: They Laughed at ElonGoogle, Amazon, and Microsoft are all hitting the same wall - data centers maxing out, power grids strained, a...Weiss Ratings | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredDistracted Americans set to miss out on quadrillionsTechnology expert and Washington D.C. insider Jeff Brown - who identified Bitcoin, Tesla, and Nvidia early - s...Brownstone Research | SponsoredSpaceX is chump change compared to Elon’s $20T ‘iPhone’Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | SponsoredYour book attachedVeteran trader Bill Poulos is giving away his 'Simple Options Trading For Beginners' book - normally $29.97 - ...Profits Run | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compass Pathways PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Compass Pathways With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
